The revised IPSS (IPSS-R) was developed aiming at a better prognostication, taking into account patients treated with best supportive care. We herein validated this model on the basis of data from 1314 patients who received BSC only as well as patients who underwent induction chemotherapy (n= 214) or allogeneic transplantation (n= 167). We could demonstrate a clear distinction of the IPSS-R risk categories with regard to survival and risk of AML evolution in all patient cohorts. When comparing IPSS-R, IPSS, WHO prognostic scoring system (WPSS) and Duesseldorf score, the best results regarding the ability to predict survival were obtained by the IPSS-R. © 2013 Elsevier Ltd.
|Titolo:||Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: A multicenter study|
|Data di pubblicazione:||2014|
|Appare nelle tipologie:||1.1 Articolo in rivista|